- ASX: PME
Pro Medicus Limited
ASX BIG FOUR - LIVE SNAPSHOT
Whitehaven Coal
(ASX:WHC)
Elixir Energy
(ASX:EXR)
Aspen Group
(ASX:APZ)
Lovisa
(ASX:LOV)
About Pro Medicus (ASX:PME)
Pro Medicus Company History
- Free Report
Get Our Full ASX Stock Analysis Report
Expert buy ranges, stop losses and detailed fundamentals for 200+ ASX stocks – free every week.
Future Outlook of Pro Medicus (ASX: PME)
Pro Medicus is well-positioned amid an ever-growing market. Despite having A$624m in contracts over 5 years assuming current contracts up for renewal are renewed, the company claims it has only penetrated 7% of the market and that it is growing by 3.5% per year. Moreover, it claims that it could benefit from adopting AI in its software, and expanding it to other health services using medical imaging, such as cardiology. The key risks are competition, key personnel risk and macroeconomic risks. That said, as advances in medical imaging continue, the data required keeps expanding. For example, an optoacoustic breast ultrasound can take up more than 10 GB of computer storage. This means downloading images, and in turn viewing them, can take a while and waiting reduces radiologists’ productivity. And in a post-COVID world, with even doctors now working from home, you don’t want you images just sitting on one computer in an office somewhere.
Is PME a Good Stock to Buy?
Pro Medicus has consistently delivered strong returns, making it one of the most closely watched technology stocks on the ASX. Its financial performance is supported by long-term contracts, high margins, and a recurring revenue model tied to imaging volumes from some of the top hospitals globally. That said, its valuation is demanding, trading at a high price-to-earnings multiple relative to the broader market. This suggests the market has priced in a significant portion of future growth. Investors should weigh this premium against the company’s strong fundamentals, debt-free balance sheet, and impressive growth pipeline. For growth-focused investors comfortable with tech-sector volatility, PME remains a quality business with strong fundamentals and global appeal.
Related Articles
Cerebras systems (NSDQ:CBRS) Dont buy this IPO just yet
Xero investors think AI is threatening the company, but Xero’s FY26 results say otherwise!
Cerebras Systems (NSDQ:CBRS): One of the biggest tech IPOs ever debuts at $350 with a OpenAI $20b de...
Megaport (ASX:MP1) up 27% A$254m of AI contracts and Latitude.sh starts paying
Michael Burry Thinks The AI Boom Is Another Dot Com Bubble And Investors Are Sleepwalking To Disaste...
Frequently Asked Questions
What does Pro Medicus do?
Is PME still growing?
Does Pro Medicus pay dividends?
Is Pro Medicus overvalued?
What are the risks of investing in PME?
Stay Sharp on the ASX
Weekly research. Independent analysis. No noise.
Free forever · Unsubscribe anytime
